Current Cancer Drug Targets
ISSN 1568-0096 · Bentham Science Publishers · United Arab Emirates · active 1956–2026
Flagged for closer checking
Publisher listed on Beall's archive (frozen 2017). Cross-check with DOAJ and Think.Check.Submit before submission.
This is a screening signal, not a verdict. How this check works.
Metrics
“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.
Indexing & access
Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.
Scope
Frequently asked
Is Current Cancer Drug Targets a predatory journal?
Our screening flags Current Cancer Drug Targets as a possible predatory venue because its publisher appears on Beall's archive, which has been frozen since 2017. Treat this as a prompt to check carefully, not a verdict: verify against DOAJ and Think. Check. Submit before submitting.
Is Current Cancer Drug Targets indexed in Scopus or Web of Science?
Per our venue index, Current Cancer Drug Targets appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.
What is Current Cancer Drug Targets's impact?
Papers in Current Cancer Drug Targets are cited about 1.8 times each within two years of publication, and Scimago places it in Q2, with an h-index of 114. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.
Is Current Cancer Drug Targets open access?
We hold no reliable open-access classification for Current Cancer Drug Targets. Check the journal's own site for its access model and any article processing charge.